Purchase Order 75F40123P00246
Award Date 8/17/23
Potential Completion Date 12/11/28
Potential Value $535K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
San Diego, CA 92122, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
2
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Food and Drug Administration awarded a $233.7K firm fixed-price purchase order to Illumina, Inc. for an Illumina NextSeq 2000 Sequencing System plus one option year of post-warranty maintenance. The award was issued on June 17, 2024, with an ultimate completion date of July 23, 2026. The equipment will be delivered to and maintained at the FDA's National Center for Toxicological Research in Jefferson, Arkansas, though the place of performance is listed as Singapore. No set-aside...
- The Food and Drug Administration (FDA) awarded a purchase order to Illumina, Inc. for an Illumina MiSeq i100Plus Sequencing System with a ceiling value of $97,054. The contract, which carries no set-aside designation, was awarded on September 18, 2025, with an ultimate completion date of October 20, 2025. The MiSeq i100Plus is an advanced DNA and RNA sequencing instrument that enables genomic analysis and research applications. Performance will take place at Illumina's San Diego, California...
- The Department of Health and Human Services Food and Drug Administration awarded a $533,378 firm fixed price purchase order to Illumina, Inc. of San Diego, California. The contract is for delivery of one Illumina NextSeq 2000 Sequencing System to support the agency's microbial metagenomics research in Berwyn Heights, Maryland. The original solicitation requested an integrated genomic sequencing system, including the NextSeq 2000 or equivalent, to generate sequence data, perform real-time...
- The Department of Health and Human Services Food and Drug Administration awarded a $534,031 firm fixed price purchase order to Illumina, Inc. of San Diego, California. The contract is for an Illumina NextSeq 2000 High Throughput Next-Generation Sequencing System to be delivered to Silver Spring, Maryland. The solicitation notice indicated the FDA requires this sequencing system to adapt standard operating procedures for its currently installed Illumina NextSeq 500 model, scale up sequencing...
- This is a firm fixed-price purchase order contract awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a leading manufacturer of genetic sequencing and genomic analysis technologies. The contract, valued at $199,714.00, is for the provision of NextSeq 550 sequencing instrument service and qualification. The contract has an ultimate completion date of August 30, 2029. Illumina, headquartered in San Diego, California, is the prime contractor and there is no set-aside designation...
- This firm fixed-price purchase order contract was awarded by the Food and Drug Administration (FDA), a civilian agency, to Illumina, Inc., a for-profit manufacturer of genomic sequencing technologies. The $576,928.00 contract is for the procurement of an Illumina NextSeq2000 Sequencing System, including associated reagents and maintenance services. The contract has a period of performance through July 20, 2026. Illumina is a key technology provider for federal scientific and diagnostic...
- The Food and Drug Administration (FDA) awarded a purchase order valued at $180,080 to Illumina, Inc. for a preventive maintenance agreement on an Illumina Next Generation Sequencer. The contract was awarded on October 24, 2019, with an ultimate completion date of November 12, 2024, and was performed at the FDA facility in Jefferson, Arkansas. This firm fixed-price contract does not utilize any set-aside designation, reflecting Illumina's specialized capabilities in genomic sequencing...
- The Department of Health and Human Services Food and Drug Administration awarded a $457,531.00 firm fixed price purchase order to Illumina, Inc., a manufacturer of genetic sequencing instruments and reagents. The contract is for the delivery of an ILLUMINA NEXTSEQ 2000 SEQUENCING SYSTEM, plus a preventative maintenance agreement, to be performed in Silver Spring, Maryland. This award does not have a set-aside designation. Illumina has a history of providing sequencing systems and related...
- The Department of Health and Human Services (HHS) Food and Drug Administration (FDA) awarded a firm fixed-price purchase order to Illumina, Inc., a for-profit manufacturer of genomic sequencing instruments and reagents, to provide an Illumina MiniSeq DNA/RNA Next Generation Sequencer (NGS) device plus four years of post-warranty maintenance support. The total potential value of the contract is $86,106.00. This procurement was not set-aside for any particular business size or type. The contract...
- This is a firm fixed-price purchase order contract awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a leading manufacturer of genetic sequencing and genomic analysis technologies. The contract is for the procurement of the MiSeq whole genome sequencing instrument, a genome sequencer, with a ceiling value of $166,207.78 and a period of performance through June 30, 2029. The contract is not set aside for any specific business designation. Illumina holds multiple federal...